Last update 29 Aug 2025

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Subsidiary Company|2024|Shanghai Shi, China

Overview

Tags

Skin and Musculoskeletal Diseases
Other Diseases
Immune System Diseases
Fc fusion protein
Antibody fusion proteins

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Hemic and Lymphatic Diseases1
Neoplasms1
Immune System Diseases1
Infectious Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Fc fusion protein1
Antibody fusion proteins1
Top 5 TargetCount
CD20 x CD471
ACVR2A(activin A receptor type 2A)1

Related

2
Drugs associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Amulirafusp alfa
Target
CD20 x CD47
Mechanism
CD20 inhibitors [+1]
Active Org.
ImmuneOnco Biopharmaceuticals (Shanghai), Inc.ImmuneOnco Biopharmaceuticals (Shanghai), Inc.
 [+1]
Originator Org.
ImmuneOnco Biopharmaceuticals (Shanghai), Inc.ImmuneOnco Biopharmaceuticals (Shanghai), Inc.
Active Indication
Systemic Lupus Erythematosus [+11]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
IMC-003 (ImmuneOnco)
Target
ACVR2A
Mechanism
ACVR2A inhibitors
Active Org.
ImmuneOnco Biopharmaceuticals (Shanghai), Inc.ImmuneOnco Biopharmaceuticals (Shanghai), Inc.
 [+1]
Originator Org.
ImmuneOnco Biopharmaceuticals (Shanghai), Inc.ImmuneOnco Biopharmaceuticals (Shanghai), Inc.
Active Indication
Pulmonary Arterial Hypertension [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
5
Clinical Trials associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
NCT06788431
/ RecruitingPhase 2
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation IIT Clinical Study to Evaluate the Efficacy and Safety of Injectable IMC-001 in Patients With Recent Acute Coronary Syndrome (ACS) Who Are Receiving Optimal Medical Therapy After PCI Treatment
NCT06535412
/ Not yet recruitingPhase 1/2
A Multi-center, Randomized, Double-blind, Placebo Control Phase 1b/II Study to Evaluate the Safety and Efficacy of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
NCT06557174
/ Not yet recruitingPhase 1/2
A Phase Ib/III Multi-center, Randomized and Positive Control Study to Evaluate IMC-002 Safety and Efficacy in in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
100 Clinical Results associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Login to view more data
100 Deals associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Login to view more data
100 Translational Medicine associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
1
Phase 2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Amulirafusp alfa
 ( CD20 x CD47 )		Systemic Lupus Erythematosus
More
Phase 1/2
IMC-003 (ImmuneOnco)
 ( ACVR2A )		Pulmonary Arterial Hypertension
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free